Urinary Cadmium and Age-related Macular Degeneration

Jay C. Erie, Jonathan A. Good, John A. Butz, David O. Hodge, Jose S Pulido

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: To evaluate the association between urinary and blood cadmium (Cd) levels with age-related macular degeneration (AMD). Design: Prospective case-control study. Methods: In 53 participants older than 60 years with AMD in both eyes and in 53 age-matched (± 3 years) controls without AMD, Cd levels were measured in blood and urine specimens (with and without creatinine adjustment) by using inductively coupled plasma-mass spectrometry. Data on age, gender, smoking status, and family history were obtained. By using color stereoscopic fundus photographs, the degree of AMD was graded using the Age-Related Eye Disease Study's 4-stage AMD severity scale. The inclusion criterion for AMD cases was a photographic severity level of two to four in both eyes. Median blood and urine Cd and median urine Cd/creatinine concentrations in cases and controls were compared by using the rank-sum test, stratifying for smoking status. Results: Current and former smokers with AMD had median urine Cd/creatinine levels (1.18 μg/g; range, 0.84 to 1.44 μg/g) that were 97% higher than smokers without AMD (0.60 μg/g; range, 0.49 to 0.90 μg/g; P = .02), 111% higher than never smokers with AMD (0.56 μg/g; range, 0.40 to 0.80 μg/g; P <.001) and 107% higher than never smokers without AMD (0.57 μg/g; 0.40 to 0.65 μg/g; P <.001). Blood Cd levels, indicative of short-term exposure levels, were not associated with AMD (P ≥ .06). Conclusions: A higher urinary Cd level, which reflects the total body burden of Cd, was associated with AMD in smokers. Accumulated Cd exposure may be important in the development of smoking-related AMD.

Original languageEnglish (US)
JournalAmerican Journal of Ophthalmology
Volume144
Issue number3
DOIs
StatePublished - Sep 2007

Fingerprint

Macular Degeneration
Cadmium
Urine
Creatinine
Smoking
Body Burden
Social Adjustment
Eye Diseases
Nonparametric Statistics
Case-Control Studies
Mass Spectrometry
Color

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Urinary Cadmium and Age-related Macular Degeneration. / Erie, Jay C.; Good, Jonathan A.; Butz, John A.; Hodge, David O.; Pulido, Jose S.

In: American Journal of Ophthalmology, Vol. 144, No. 3, 09.2007.

Research output: Contribution to journalArticle

Erie, Jay C. ; Good, Jonathan A. ; Butz, John A. ; Hodge, David O. ; Pulido, Jose S. / Urinary Cadmium and Age-related Macular Degeneration. In: American Journal of Ophthalmology. 2007 ; Vol. 144, No. 3.
@article{492ddb29d079449b9755b313be999311,
title = "Urinary Cadmium and Age-related Macular Degeneration",
abstract = "Purpose: To evaluate the association between urinary and blood cadmium (Cd) levels with age-related macular degeneration (AMD). Design: Prospective case-control study. Methods: In 53 participants older than 60 years with AMD in both eyes and in 53 age-matched (± 3 years) controls without AMD, Cd levels were measured in blood and urine specimens (with and without creatinine adjustment) by using inductively coupled plasma-mass spectrometry. Data on age, gender, smoking status, and family history were obtained. By using color stereoscopic fundus photographs, the degree of AMD was graded using the Age-Related Eye Disease Study's 4-stage AMD severity scale. The inclusion criterion for AMD cases was a photographic severity level of two to four in both eyes. Median blood and urine Cd and median urine Cd/creatinine concentrations in cases and controls were compared by using the rank-sum test, stratifying for smoking status. Results: Current and former smokers with AMD had median urine Cd/creatinine levels (1.18 μg/g; range, 0.84 to 1.44 μg/g) that were 97{\%} higher than smokers without AMD (0.60 μg/g; range, 0.49 to 0.90 μg/g; P = .02), 111{\%} higher than never smokers with AMD (0.56 μg/g; range, 0.40 to 0.80 μg/g; P <.001) and 107{\%} higher than never smokers without AMD (0.57 μg/g; 0.40 to 0.65 μg/g; P <.001). Blood Cd levels, indicative of short-term exposure levels, were not associated with AMD (P ≥ .06). Conclusions: A higher urinary Cd level, which reflects the total body burden of Cd, was associated with AMD in smokers. Accumulated Cd exposure may be important in the development of smoking-related AMD.",
author = "Erie, {Jay C.} and Good, {Jonathan A.} and Butz, {John A.} and Hodge, {David O.} and Pulido, {Jose S}",
year = "2007",
month = "9",
doi = "10.1016/j.ajo.2007.05.020",
language = "English (US)",
volume = "144",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Urinary Cadmium and Age-related Macular Degeneration

AU - Erie, Jay C.

AU - Good, Jonathan A.

AU - Butz, John A.

AU - Hodge, David O.

AU - Pulido, Jose S

PY - 2007/9

Y1 - 2007/9

N2 - Purpose: To evaluate the association between urinary and blood cadmium (Cd) levels with age-related macular degeneration (AMD). Design: Prospective case-control study. Methods: In 53 participants older than 60 years with AMD in both eyes and in 53 age-matched (± 3 years) controls without AMD, Cd levels were measured in blood and urine specimens (with and without creatinine adjustment) by using inductively coupled plasma-mass spectrometry. Data on age, gender, smoking status, and family history were obtained. By using color stereoscopic fundus photographs, the degree of AMD was graded using the Age-Related Eye Disease Study's 4-stage AMD severity scale. The inclusion criterion for AMD cases was a photographic severity level of two to four in both eyes. Median blood and urine Cd and median urine Cd/creatinine concentrations in cases and controls were compared by using the rank-sum test, stratifying for smoking status. Results: Current and former smokers with AMD had median urine Cd/creatinine levels (1.18 μg/g; range, 0.84 to 1.44 μg/g) that were 97% higher than smokers without AMD (0.60 μg/g; range, 0.49 to 0.90 μg/g; P = .02), 111% higher than never smokers with AMD (0.56 μg/g; range, 0.40 to 0.80 μg/g; P <.001) and 107% higher than never smokers without AMD (0.57 μg/g; 0.40 to 0.65 μg/g; P <.001). Blood Cd levels, indicative of short-term exposure levels, were not associated with AMD (P ≥ .06). Conclusions: A higher urinary Cd level, which reflects the total body burden of Cd, was associated with AMD in smokers. Accumulated Cd exposure may be important in the development of smoking-related AMD.

AB - Purpose: To evaluate the association between urinary and blood cadmium (Cd) levels with age-related macular degeneration (AMD). Design: Prospective case-control study. Methods: In 53 participants older than 60 years with AMD in both eyes and in 53 age-matched (± 3 years) controls without AMD, Cd levels were measured in blood and urine specimens (with and without creatinine adjustment) by using inductively coupled plasma-mass spectrometry. Data on age, gender, smoking status, and family history were obtained. By using color stereoscopic fundus photographs, the degree of AMD was graded using the Age-Related Eye Disease Study's 4-stage AMD severity scale. The inclusion criterion for AMD cases was a photographic severity level of two to four in both eyes. Median blood and urine Cd and median urine Cd/creatinine concentrations in cases and controls were compared by using the rank-sum test, stratifying for smoking status. Results: Current and former smokers with AMD had median urine Cd/creatinine levels (1.18 μg/g; range, 0.84 to 1.44 μg/g) that were 97% higher than smokers without AMD (0.60 μg/g; range, 0.49 to 0.90 μg/g; P = .02), 111% higher than never smokers with AMD (0.56 μg/g; range, 0.40 to 0.80 μg/g; P <.001) and 107% higher than never smokers without AMD (0.57 μg/g; 0.40 to 0.65 μg/g; P <.001). Blood Cd levels, indicative of short-term exposure levels, were not associated with AMD (P ≥ .06). Conclusions: A higher urinary Cd level, which reflects the total body burden of Cd, was associated with AMD in smokers. Accumulated Cd exposure may be important in the development of smoking-related AMD.

UR - http://www.scopus.com/inward/record.url?scp=34548264589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548264589&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2007.05.020

DO - 10.1016/j.ajo.2007.05.020

M3 - Article

C2 - 17631267

AN - SCOPUS:34548264589

VL - 144

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -